Effect of dorzolamide-timolol fixed combination prophylaxis on intraocular pressure spikes after intravitreal bevacizumab injection

International Journal of Ophthalmology

Volumn 8, Issue 3, 2015, Pages 496-500

  Ozcaliskan, Sehnaz ^a   Ozturk, Faruk ^b   Yilmazbas, Pelin ^c   Beyazyildiz, Ozlem ^d  

^a Ba kale Devlet Hastanesi   (Turkey)

^b YILDIRIM BEYAZIT UNIVERSITY   (Turkey)

^c Ulucanlar Training and Research Hospital 3st Eye Clinic   (Turkey)

^d Department of Ophthalmology Gynecology and Pediactric Diseases Hospital   (Turkey)

Author keywords

Bevacizumab; Dorzolamid timolol combination; Intraocular pressure

Indexed keywords

EID: 84938886007     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2015.03.11     Document Type: Article

References (31)

1. El Chehab H, Le Corre A, Agard E, Ract-Madoux G, Coste O, Dot C. Effect of topical pressure-lowering medication on prevention of intraocular pressure spikes after intravitreal injection. Eur J Ophthalmol 2013; 23(3): 277-283.
2. D'Amico DJ, Masonson HN, Patel M, Adamis AP, Cunningham ET Jr, Guyer DR, Katz B. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology2006; 113(6): 992-1001.
3. Sampat KM, Garg SJ. Complications of intravitreal injections. Curr Opin Ophthalmol 2010; 21(3): 178-183.
4. Sönmez K, Öztürk F. Complications of intravitreal triamcinolone acetonide for macular edema and predictive factors for intraocular pressure elevation. Int J Ophthalmol 2012; 5(6): 719-725.
5. Kim JE, Mantravadi AV, Hur EY, Covert DJ. Short-term intraocular pressure changes immediately after intravitreal injections of anti-vascular endothelial growth factor agents. Am J Ophthalmol 2008; 146(6): 930-934.
6. Kubota T, Okabe H, Hisatomi T, Yamakiri K, Sakamoto T, Tawara A. Ultrastructure of the trabecular meshwork in secondary glaucoma eyes after intravitreal triamcinolone acetonide. J Glaucoma 2006; 15(2): 117-119.
7. Mathalone N, Arodi-Golan A, Sar S, Wolfson Y, Shalem M, Lavi I, Geyer O. Sustained elevation of intraocular pressure after intravitreal injections of bevacizumab in eyes with neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol2012; 250(10): 1435-1440.
8. Hoang QV, Tsuang AJ, Gelman R, Mendonca LS, Della Torre KE, Jung JJ, Freund KB. Clinical predictors of sustained intraocular pressure elevation due to intravitreal anti-vascular endothelial growth factor therapy. Retina 2013; 33(1): 179-187.
9. Jonas JB, Kreissig I, Degenring R. Intravitreal triamcinolone acetonide for treatment of intraocular proliferative, exudative, and neovascular diseases. Prog Retin Eye Res 2005; 24(5): 587-611.
10. Clark AF, Wilson K, McCartney MD, Miggans ST, Kunkle M, Howe W. Glucocorticoid-induced formation of cross-linked actin networks in cultured human trabecular meshwork cells. Invest Ophthalmol Vis Sci 1994; 35(1): 281-294.
11. Hollands H, Wong J, Bruen R, Campbell RJ, Sharma S, Gale J. Short-term intraocular pressure changes after intravitreal injection of bevacizumab. Can J Ophthalmol 2007; 42(6): 807-811.
12. Bakri SJ, Pulido JS, McCannel CA, Hodge DO, Diehl N, Hillemeier J. Immediate intraocular pressure changes following intravitreal injections of triamcinolone, pegaptanib, and bevacizumab. Eye (Lond) 2009; 23(1): 181-185.
13. Quigley HA, Anderson DR. Distribution of axonal transport blockade by acute intraocular pressure elevation in the primate optic nerve head. Invest Ophthalmol Vis Sci 1977; 16(7): 640-644.
14. Kim KS, Jee D. Effect of the Honan intraocular pressure reducer on intraocular pressure increase following intravitreal injection using the tunneled scleral technique. Jpn J Ophthalmol 2011; 55(6): 632-637.
15. Hernaez-Ortega MC, Soto-Pedre E. Use of the Honan balloon as a compression device for intravitreal triamcinolone acetonide injection. Ophthalmic Surg Lasers Imaging 2007; 38(1): 87-88.
16. Chang W, Chung M. Efficacy of anterior chamber paracentesis after intravitreal triamcinolone injection. Eur J Ophthalmol2007; 17(5): 776-779.
17. Knip MM, Völimöki J. Effects of pegaptanib injections on intraocular pressure with and without anterior chamber paracentesis: a prospective study. Acta Ophthalmol 2012; 90(3): 254-258.
18. Frenkel MP, Haji SA, Frenkel RE. Effect of prophylactic intraocular pressure-lowering medication on intraocular pressure spikes after intravitreal injections. Arch Ophthalmol 2010; 128(12): 1523-1527.
19. Kim GN, Han YS, Chung IY, Seo SW, Park JM, Yoo JM. Effect of Dorzolamide/Timolol or Brinzolamide/Timolol prophylaxis on intravitreal anti-VEGF injection-induced intraocular hypertension. Semin Ophthalmol 2013; 28(2): 61-67.
20. Aiello LP, Brucker AJ, Chang S, Cunningham ET Jr, D'Amico DJ, Flynn HW Jr, Grillone RL, Hutcherson S, Liebmann JM, O'Brien TP, Scott IU, Spaide RF, Ta C, Trese MT. Evolving guidelines for intravitreous injections. Retina 2004; 24(5 Suppl): S3-19.
21. Wu L, Evans T. Immediate changes in intraocular pressure after an intravitreal injection of 2. 5 mg of bevacizumab. Arch Soc Esp Oftalmol2010; 85(11): 364-369.
22. Kotliar K, Maier M, Bauer S, Feucht N, Lohmann C, Lanzl I. Effect of intravitreal injections and volume changes on intraocular pressure: clinical results and biomechanical model. Acta Ophthalmol Scand 2007; 85(7): 777-781.
23. Asrani S, Zeimer R, Wilensky J, Gieser D, Vitale S, Lindenmuth K. Large diurnal fluctuations in intraocular pressure are an independent risk factor in patients with glaucoma. J Glaucoma 2000; 9(2): 134-142.
24. Gonzalez I, Pablo LE, Pueyo M, Ferrer E, Melcon B, Abecia E, Honrubia FM. Assessment of diurnal tensional curve in early glaucoma damage. Int Ophthalmol 1996; 20(1-3): 113-115.
25. Theoulakis PE, Lepidas J, Petropoulos IK, Livieratou A, Brinkmann CK, Katsimpris JM. Effect of brimonidine/timolol fixed combination on preventing the short-term intraocular pressure increase after intravitreal injection of ranibizumab. Klin Monbl Augenheilkd 2010; 227(4): 280-284.
26. Clineschmidt CM, Williams RD, Snyder E, Adamsons IA. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol or dorzolamide. Dorzolamide-Timolol Combination Study Group. Ophthalmology1998; 105(10): 1952-1959.
27. Francis BA, Du LT, Berke S, Ehrenhaus M, Minckler DS. Comparing the fixed combination dorzolamide-timolol (Cosopt) to concomitant administration of 2% dorzolamide (Trusopt) and 0. 5% timolol-a randomized controlled trial and a replacement study. J Clin Pharm Ther2004; 29(4): 375-380.
28. Kerimoglu H, Ozturk BT, Bozkurt B, Okka M, Okudan S. Does lens status affect the course of early intraocular pressure and anterior chamber changes after intravitreal injection? Acta Ophthalmol 2011; 89(2): 138-142.
29. Gismondi M, Salati C, Salvetat ML, Zeppieri M, Brusini P. Short-term effect of intravitreal injection of Ranibizumab (Lucentis) on intraocular pressure. J Glaucoma 2009; 18(9): 658-661.
30. Hoang QV, Mendonca LS, Della Torre KE, Jung JJ, Tsuang AJ, Freund KB. Effect on intraocular pressure in patients receiving unilateral intravitreal anti-vascular endothelial growth factor injections. Ophthalmology 2012; 119(2): 321-326.
31. Bhartiya S, Bali SJ, Sharma R, Chaturvedi N, Dada T. Comparative evaluation of TonoPen AVIA, Goldmann applanation tonometry and non-contact tonometry. Int Ophthalmol 2011;31(4):297-302.